Lonza Group - LZAGY Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$46.69
▼ -0.16 (-0.34%)

This chart shows the closing price for LZAGY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lonza Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LZAGY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LZAGY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Lonza Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $46.69.

This chart shows the closing price for LZAGY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 5 contributing investment analysts is to moderate buy stock in Lonza Group. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/1/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/30/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/28/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/27/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/25/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/24/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/23/2023

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/14/2023HSBCInitiated CoverageBuy
5/17/2023Stifel NicolausInitiated CoverageHold
2/10/2023William BlairReiterated RatingOutperform
12/7/2022Credit Suisse GroupLower TargetOutperform ➝ OutperformCHF 700 ➝ CHF 580
10/4/2022Sanford C. BernsteinInitiated CoverageOutperform
8/10/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight
8/1/2022Royal Bank of CanadaBoost TargetCHF 650 ➝ CHF 670
7/25/2022JPMorgan Chase & Co.Lower TargetCHF 900 ➝ CHF 770
7/7/2022Credit Suisse GroupLower TargetOutperform ➝ OutperformCHF 750 ➝ CHF 700
7/6/2022Deutsche Bank AktiengesellschaftLower TargetBuy ➝ BuyCHF 835 ➝ CHF 702
7/5/2022CitigroupUpgradeNeutral ➝ Buy
5/20/2022Royal Bank of CanadaUpgradeSector Perform ➝ Outperform
4/4/2022Morgan StanleyLower TargetEqual Weight ➝ Equal WeightCHF 800 ➝ CHF 785
2/10/2022Stifel NicolausUpgradeHold ➝ Buy
1/4/2022JPMorgan Chase & Co.Boost TargetCHF 850 ➝ CHF 900
10/20/2021UBS GroupUpgradeNeutral ➝ Buy
10/15/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
9/17/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight
9/8/2021JPMorgan Chase & Co.Reiterated RatingOverweight
7/29/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
7/29/2021Societe GeneraleReiterated RatingBuy
7/28/2021CitigroupReiterated RatingNeutral
7/28/2021Credit Suisse GroupReiterated RatingOutperform
7/2/2021Societe GeneraleReiterated RatingBuy
6/8/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy
5/11/2021Morgan StanleyReiterated RatingOverweight
2/23/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
2/16/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
2/11/2021William BlairReiterated RatingOutperform
2/10/2021Berenberg BankReiterated RatingBuy
2/2/2021Morgan StanleyReiterated RatingOverweight
1/8/2021Morgan StanleyReiterated RatingOverweight
11/11/2020UBS GroupReiterated RatingNeutral
11/9/2020KeyCorpInitiated CoverageSector Weight ➝ Sector Weight
10/21/2020Societe GeneraleReiterated RatingBuy
10/2/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
9/14/2020Morgan StanleyReiterated RatingOverweight
9/4/2020Societe GeneraleReiterated RatingBuy
8/13/2020Credit Suisse GroupReiterated RatingOutperform
7/30/2020Morgan StanleyReiterated RatingOverweight
7/8/2020UBS GroupReiterated RatingNeutral
6/24/2020Morgan StanleyReiterated RatingOverweight
5/14/2020UBS GroupDowngradeBuy ➝ Neutral
1/31/2019Bank of AmericaDowngradeBuy ➝ Neutral
(Data available from 9/23/2018 forward)

News Sentiment Rating

0.60 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2023
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/25/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
8/24/2023
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/23/2023

Current Sentiment

  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.
Lonza Group logo
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was incorporated in 1897 and is headquartered in Basel, Switzerland.
Read More

Today's Range

Now: $46.69
Low: $46.65
High: $47.05

50 Day Range

MA: $55.29
Low: $46.69
High: $64.27

52 Week Range

Now: $46.69
Low: $43.85
High: $66.00

Volume

165,641 shs

Average Volume

75,347 shs

Market Capitalization

$34.77 billion

P/E Ratio

N/A

Dividend Yield

0.18%

Beta

0.9

Frequently Asked Questions

What sell-side analysts currently cover shares of Lonza Group?

The following equities research analysts have issued reports on Lonza Group in the last twelve months: Credit Suisse Group AG, HSBC Holdings plc, Sanford C. Bernstein, Stifel Nicolaus, and William Blair.
View the latest analyst ratings for LZAGY.

What is the current price target for Lonza Group?

0 Wall Street analysts have set twelve-month price targets for Lonza Group in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Lonza Group in the next year.
View the latest price targets for LZAGY.

What is the current consensus analyst rating for Lonza Group?

Lonza Group currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for LZAGY.

What other companies compete with Lonza Group?

Other companies that are similar to Lonza Group include AmerisourceBergen, DexCom, Centene, Biogen and Haleon. Learn More about companies similar to Lonza Group.

How do I contact Lonza Group's investor relations team?

Lonza Group's physical mailing address is Muenchensteinerstrasse 38, Basel V8, 4002. The company's listed phone number is (161) 316-8111 and its investor relations email address is invest[email protected]. The official website for Lonza Group is www.lonza.com. Learn More about contacing Lonza Group investor relations.